Metly is an AI-powered platform built for pharmaceutical business development teams that uses AI agents to continuously scan public and proprietary data to surface licensing and manufacturing opportunities and assess strategic fit. The platform integrates discovery with outreach tools so teams can contact relevant partners and shorten timelines that today rely on personal contacts, industry events, and spreadsheets. Metly already hosts more than 35,000 licensed products from 550 global licensors. The company says its product simplifies and accelerates every step of partnership discovery and execution. Metly is expanding into the US and China. The new funding will support scaling its AI technology, growing technical and commercial teams, and accelerating international growth.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2025